•AMENDMENT UNDER 37 C.F.R. § 1.116 `

Application No.: 10/537,767

Attorney Docket No.: Q88255

REMARKS

Upon entry of the Amendment, claims 1-9 and 11 are pending in the application. Claims 1, 6, 8, and 9 are amended. Claim 10 is canceled. Claim 11 is new.

I. Claim Rejections - 35 U.S.C. § 112

(A) Claims 1-7 are rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the written description requirement.

Further, claims 8-10 are rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the written description requirement.

Referring to page 4 of the Office Action, the Examiner asserts that Applicants have failed to describe the correlation of structure to function relationship in the amino acid sequences in which from 1 to 10 amino acids are deleted, substituted, and/or inserted in the amino acid sequence of SEQ ID NO: 2 or 4.

Claim 1 presently recites a polypeptide which comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 and which binds to Akt2.

Claim 2 recites an isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.

Claim 6 presently recites a method for screening a substance which inhibits binding of a polypeptide described in claim 1.

Applicants respectfully submit that the specification provides written description support for a polypeptide which comprises the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4. The specification describes the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The specification provides evidence that the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 2 and SEQ ID NO: 2 and SEQ ID NO: 3 and SEQ ID NO: 3 and SEQ ID NO: 3 and SEQ ID NO: 4 and SEQ ID NO: 3 and SEQ ID NO: 4 and SEQ ID NO: 4 and SEQ ID NO: 3 and SEQ ID NO: 4 and 5 and 5

AMENDMENT UNDER 37 C.F.R. § 1.116 '

Application No.: 10/537,767

Attorney Docket No.: Q88255

NO: 4 both bind to Akt2. In this regard, the specification provides written description support for claims 1, 2, and 6.

Claims 3-5 depend directly or indirectly from claim 1 or 2. Claims 7-9 depend directly or indirectly from claim 6. In this regard, the specification provides written description support for claims 3-5 and 7-9 for at least the same reasons as claims 1, 2, and 6.

(B) Claims 1-7 are rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the enablement requirement.

Further, claims 8-10 are rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the enablement requirement.

For the same reasons provided above, Applicants respectfully submit that the specification provides sufficient guidance and support so that a person skilled in the art can make and use the amino acid sequences recited in claims 1, 2, and 6.

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

AMENDMENT UNDER 37 C.F.R. § 1.116 '

Application No.: 10/537,767

Attorney Docket No.: Q88255

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 58,490

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565
CUSTOMER NUMBER

Date: August 13, 2007